Prostate cancer research
Genes flag risk of prostate cancer
A/Prof Jyotsna Batra
Jyotsna is an independent group leader at the Queensland University of Technology, based at the Translational Research Institute in Brisbane.
A/Prof Jyotsna Batra's research
Through her previous Cure Cancer Australia grants in 2014 and 2015, Jyotsna has identified genetic variations - specifically in the regulation of proteins encoded in a person’s DNA - that predispose men to prostate cancer. These genetic variations are promising therapeutic targets for new treatments for the disease.
“The 2018 funding will allow me to take the lead from previous work and continue to progress to testing on patients,” she says.
“It’s given me the freedom to carry out novel and advanced research, which wouldn’t have been otherwise possible".
Identifying risk
Jyotsna believes that changes in gene sequences, when used alongside the traditional Prostate-Specific Antigen blood test (which can be unreliable on its own), can serve as effective biomarkers to identify men predisposed to developing prostate cancer.
These biomarkers can also help distinguish the slowly progressive from the aggressive form of the disease.
“By analysing the DNA of around 50,000 individuals, half of which belongs to prostate cancer patients, we’ve identified 100 genetic variations associated with prostate cancer risk”, she says. “They can collectively explain about 30% of the inherited component of the disease”.
The human touch
As much of her research is conducted on samples taken directly from prostate cancer sufferers, Jyotsna understands the urgency of her work.
“I can feel patients’ anxiety in the initial stages of diagnosis,” she says. “Affected men are keen to find out whether they should wait and watch, or start aggressive treatment as soon as possible”.
Jyotsna cites focus and passion as essential attributes of a successful researcher and believes ‘smart work’ can deliver success.
In her spare time, Jyotsna enjoys reading, travel and spending time with her young son.
Jyotsna is funded by Cure Cancer Australia through the Cancer Australia Priority-driven Cancer Support Scheme.
Jyotsna is based at the Translational Research Institute.
Related blog posts
World Cancer Day: Meet Cure Cancer's 2025 researchers
Together, we’re creating breakthroughs: A look back at 202...
Multi-Omics 2024 and Cure Cancer's impact on innovation in c...
In the media
Yuchen Feng named Researcher of the Year 2024
'Google Maps' of cancer offers better treatment
Cure Cancer profiles the work and lab of young guns Dr Hao and Dr Stamp
Lunch & Learn series
Find out about the latest developments in cancer research first hand from our researchers and the impact of your support.
We take on every cancer
Cure Cancer funds ground breaking research across every cancer, no matter the size or rarity.
We aim to maximise our impact, save millions of lives, and leaves no one behind.
Blood Cancer
Bone Cancer
Brain Cancer
Breast Cancer
Childhood Cancer
Gastro-Intestinal Cancer
Gynaecological Cancer
Prostate Cancer
Our research grant program
We are dedicated to funding new innovative cancer research projects, giving talented emerging cancer researchers the opportunity to pursue their innovative ideas across diverse areas of cancer research.
Through our Research Grants Program, we commit to back new ideas from the most brilliant minds in cancer research.
Let's stay in touch
To receive updates on our work, campaigns and our impact in cancer research, subscribe to our newsletter.
